LYEL RSI Chart
Last 7 days
-0.4%
Last 30 days
-15.9%
Last 90 days
42.9%
Trailing 12 Months
-15.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 63.5M | 42.4M | 21.3M | 130.0K |
2022 | 29.2M | 47.7M | 66.2M | 84.7M |
2021 | 8.9M | 8.5M | 10.0M | 10.7M |
2020 | 0 | 3.0M | 5.4M | 7.8M |
2019 | 0 | 0 | 0 | 657.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 09, 2024 | lee gary k. | acquired | - | - | 40,000 | chief scientific officer |
Feb 09, 2024 | newton charles w. | acquired | - | - | 40,000 | chief financial officer |
Feb 09, 2024 | hill stephen j. | acquired | - | - | 40,000 | chief operating officer |
Feb 09, 2024 | lang matthew | acquired | - | - | 50,000 | chief business officer |
Feb 09, 2024 | seely lynn | acquired | - | - | 200,000 | president and ceo |
Aug 15, 2023 | klausner richard | sold | -132,286 | 2.28 | -58,020 | - |
Sep 23, 2022 | klausner richard | sold | -71,041 | 6.4001 | -11,100 | - |
Sep 08, 2022 | bishop hans edgar | acquired | 14,538 | 0.1 | 145,380 | - |
Feb 23, 2022 | bishop hans edgar | acquired | 99,342 | 0.1 | 993,428 | - |
Dec 14, 2021 | friedman cathy | acquired | - | - | 218,722 | - |
Which funds bought or sold LYEL recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 13, 2024 | FRANKLIN RESOURCES INC | unchanged | - | 24,132 | 185,569 | -% |
May 13, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.85 | 23,377 | 190,719 | -% |
May 13, 2024 | GEODE CAPITAL MANAGEMENT, LLC | added | 2.02 | 1,319,680 | 8,958,880 | -% |
May 13, 2024 | XPONANCE, INC. | added | 3.79 | 3,851 | 23,794 | -% |
May 13, 2024 | FMR LLC | reduced | -0.7 | 765,323 | 6,175,450 | -% |
May 13, 2024 | UBS Group AG | reduced | -8.98 | 19,618 | 444,167 | -% |
May 13, 2024 | HRT FINANCIAL LP | sold off | -100 | -963,000 | - | -% |
May 13, 2024 | Lighthouse Investment Partners, LLC | new | - | 274,294 | 274,294 | 0.01% |
May 13, 2024 | Nuveen Asset Management, LLC | added | 16.8 | 484,871 | 1,900,080 | -% |
May 13, 2024 | XTX Topco Ltd | reduced | -28.75 | -54,559 | 246,903 | 0.03% |
Unveiling Lyell Immunopharma, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Lyell Immunopharma, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 49.2B | 6.8B | -8.24 | 7.18 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.7B | 2.0B | -56.37 | 9.34 | ||||
BMRN | 15.1B | 2.5B | 73.61 | 6.12 | ||||
INCY | 12.8B | 3.8B | 17.19 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.4B | 107.9M | -9.93 | 48.09 | ||||
APLS | 5.0B | 524.1M | -11.99 | 9.55 | ||||
AXSM | 3.7B | 251.0M | -12.4 | 14.64 | ||||
ARWR | 2.8B | 240.7M | -6.04 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.4K | 3.01 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.9B | 996.6M | -4.75 | 1.9 | ||||
CRBP | 456.3M | 881.7K | -13.52 | 481.06 | ||||
INO | 297.2M | 4.9M | -2.38 | 61.07 | ||||
IBIO | 16.2M | 2.1M | -0.7 | 7.61 |
Lyell Immunopharma, Inc. News
Income Statement (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Revenue | -100.0% | - | 0.00 | 0.00 | 0.00 | 24.00 | 48.00 | 0.00 | 36.00 | 19.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 1.00 | 3.00 | - |
Operating Expenses | -6.6% | 56.00 | 60.00 | 59.00 | 66.00 | 63.00 | 63.00 | 66.00 | 73.00 | 69.00 | 50.00 | 52.00 | 65.00 | 58.00 | 42.00 | 38.00 | 106 | - |
S&GA Expenses | -100.0% | - | 13.00 | 16.00 | 19.00 | 19.00 | 26.00 | 26.00 | 30.00 | 34.00 | 32.00 | 21.00 | 19.00 | 17.00 | 15.00 | 14.00 | 10.00 | - |
R&D Expenses | -8.1% | 43.00 | 47.00 | 44.00 | 47.00 | 45.00 | 38.00 | 42.00 | 44.00 | 36.00 | 19.00 | 31.00 | 46.00 | 42.00 | 35.00 | 25.00 | 97.00 | - |
Net Income | -14.6% | -60.67 | -52.93 | -50.85 | -63.89 | -66.96 | -8.40 | -70.25 | -36.32 | -68.14 | -83.71 | -48.87 | -62.59 | -55.04 | -38.86 | -35.72 | -100 | - |
Net Income Margin | 2.7% | 0.00 | 0.00 | -8.94* | -4.94* | -2.86* | -2.16* | -3.91* | -4.97* | -9.03* | -23.48* | -20.49* | -22.73* | -25.74* | -26.36* | - | - | - |
Free Cashflow | -3.4% | -42.05 | -40.66 | -37.88 | -40.09 | -47.74 | -44.85 | -39.89 | -51.50 | -57.58 | -43.48 | -37.09 | -58.39 | -52.79 | -51.61 | - | - | - |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -7.4% | 694 | 750 | 795 | 835 | 880 | 938 | 977 | 1,022 | 1,072 | 1,127 | 1,198 | 1,230 | 908 |
Current Assets | -3.7% | 534 | 555 | 587 | 606 | 624 | 651 | 660 | 667 | 626 | 626 | 631 | 835 | 618 |
Cash Equivalents | -13.5% | 126 | 146 | 286 | 224 | 109 | 124 | 116 | 206 | 223 | 294 | 394 | 564 | 141 |
Net PPE | -4.7% | 98.00 | 103 | 108 | 114 | 119 | 123 | 126 | 128 | 126 | 120 | 116 | 110 | 77.00 |
Liabilities | -4.2% | 91.00 | 95.00 | 97.00 | 98.00 | 97.00 | 104 | 157 | 154 | 191 | 198 | 212 | 208 | 190 |
Current Liabilities | -6.3% | 32.00 | 35.00 | 35.00 | 34.00 | 31.00 | 37.00 | 51.00 | 50.00 | 41.00 | 47.00 | 59.00 | 64.00 | 49.00 |
Shareholder's Equity | -7.9% | 603 | 655 | 698 | 737 | 784 | 833 | 820 | 868 | 881 | 930 | 986 | 1,022 | - |
Retained Earnings | -6.1% | -1,062 | -1,002 | -949 | -898 | -834 | -767 | -759 | -688 | -652 | -584 | -500 | -451 | -334 |
Additional Paid-In Capital | 0.6% | 1,666 | 1,657 | 1,648 | 1,638 | 1,622 | 1,608 | 1,589 | 1,565 | 1,540 | 1,516 | 1,487 | 1,474 | 41.00 |
Shares Outstanding | 0.4% | 255 | 254 | 252 | 251 | 250 | 250 | 248 | 246 | 244 | 136 | 101 | 43.00 | - |
Float | - | - | - | - | 654 | - | - | - | 1,100 | - | - | - | 2,741 | - |
Cashflow (Quarterly) | ||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
Cashflow From Operations | -3.4% | -42,016 | -40,635 | -37,686 | -39,161 | -46,212 | -40,267 | -37,103 | -44,333 | -47,852 | -33,213 | -25,492 | -33,947 | -33,597 | -26,732 | -21,628 | - | - |
Share Based Compensation | 8.2% | 9,155 | 8,463 | 10,516 | 14,223 | 13,882 | 18,363 | 19,123 | 22,410 | 22,028 | 21,178 | 13,042 | 15,249 | 12,732 | 12,971 | 9,748 | - | - |
Cashflow From Investing | 121.8% | 21,994 | -100,690 | 99,672 | 152,912 | 32,154 | 46,648 | -57,085 | 25,019 | -26,122 | -73,862 | -144,914 | -39,474 | 136,677 | 32,387 | -89,945 | - | - |
Cashflow From Financing | -96.4% | 27.00 | 759 | -143 | 1,196 | -69.00 | 863 | 4,760 | 2,457 | 2,555 | 7,399 | -531 | 393,492 | 884 | 338 | 35.00 | - | - |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||
Revenue | $ 3 | $ 65 |
Operating expenses: | ||
Research and development | 43,174 | 44,630 |
General and administrative | 13,494 | 19,279 |
Other operating income, net | (1,090) | (1,288) |
Total operating expenses | 55,578 | 62,621 |
Loss from operations | (55,575) | (62,556) |
Interest income, net | 6,819 | 4,497 |
Other income, net | 1,090 | 1,100 |
Impairment of other investments | (13,001) | (10,000) |
Total other loss, net | (5,092) | (4,403) |
Net loss | (60,667) | (66,959) |
Other comprehensive loss: | ||
Net unrealized (loss) gain on marketable securities | (310) | 3,720 |
Comprehensive loss | $ (60,977) | $ (63,239) |
Net loss per common share, basic (in dollars per share) | $ (0.24) | $ (0.27) |
Net loss per common share, diluted (in dollars per share) | $ (0.24) | $ (0.27) |
Weighted-average shares used to compute net loss per common share, basic (in shares) | 254,252 | 249,591 |
Weighted-average shares used to compute net loss per common share, diluted (in shares) | 254,252 | 249,591 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 125,650 | $ 145,647 |
Marketable securities | 400,650 | 400,576 |
Prepaid expenses and other current assets | 7,865 | 8,463 |
Total current assets | 534,165 | 554,686 |
Restricted cash | 286 | 284 |
Marketable securities, non-current | 0 | 16,506 |
Other investments | 19,000 | 32,001 |
Property and equipment, net | 97,836 | 102,654 |
Operating lease right-of-use assets | 38,695 | 39,663 |
Other non-current assets | 4,238 | 4,235 |
Total assets | 694,220 | 750,029 |
Current liabilities: | ||
Accounts payable | 4,895 | 4,817 |
Accrued liabilities and other current liabilities | 24,914 | 28,126 |
Success payment liabilities | 2,544 | 1,576 |
Total current liabilities | 32,353 | 34,519 |
Operating lease liabilities, non-current | 55,159 | 56,894 |
Other non-current liabilities | 3,551 | 3,664 |
Total liabilities | 91,063 | 95,077 |
Commitments and contingencies (Note 11) | ||
Stockholders’ equity: | ||
Preferred stock, $0.0001 par value; 10,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.0001 par value; 500,000 shares authorized at March 31, 2024 and December 31, 2023; 254,927 and 253,958 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 25 | 25 |
Additional paid-in capital | 1,666,315 | 1,657,133 |
Accumulated other comprehensive loss | (404) | (94) |
Accumulated deficit | (1,062,779) | (1,002,112) |
Total stockholders’ equity | 603,157 | 654,952 |
Total liabilities and stockholders’ equity | $ 694,220 | $ 750,029 |